Treatments in Endocrinology

, Volume 5, Issue 5, pp 326–326 | Cite as

Oral Paricalcitol

A Viewpoint by James B. Wetmore and L. Darryl Quarles
  • James B. Wetmore
  • L. Darryl Quarles
Adis Drug Profile Guest Commentary
  • 6 Downloads

References

  1. 1.
    Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004; 43(3): 572–9PubMedCrossRefGoogle Scholar
  2. 2.
    National Kidney Foundation (NFK) K/DOQI Guidelines. K/DOQI clinical practise guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 Suppl. 3: S1–201Google Scholar
  3. 3.
    Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349(5): 446–56PubMedCrossRefGoogle Scholar
  4. 4.
    Coyne D, Acharya M, Qiu P, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Kidney Dis 2006 Feb; 47(2): 263–76PubMedCrossRefGoogle Scholar
  5. 5.
    Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63(4): 1483–90PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • James B. Wetmore
    • 1
  • L. Darryl Quarles
    • 1
  1. 1.Department of Nephrology and HypertensionUniversity of Kansas Medical CenterKansas CityUSA

Personalised recommendations